We assessed whether fibrinogen concentrate as targeted first-line hemostatic therapy was more effective than placebo or a standardized transfusion algorithm in controlling coagulopathic bleeding in patients undergoing major aortic surgery.
Acquired hypofibrinogenemia is a common coagulopathy associated with cardiac surgery, and baseline plasma fibrinogen levels have been reported to decrease by 34% to 58% during CPB. [7] [8] [9] Because fibrinogen is the precursor to fibrin, low fibrinogen levels can compromise fibrin-based clot formation. Fibrin clot quality, recorded using the thromboelastometry-based FIBTEM test (ROTEM device; TEM International, Munich, Germany), has been shown to decrease by 38% to 52% during CPB. 10, 11 Time spent on CPB is therefore an important factor and typically greater for complex cardiac surgeries accompanied by substantial blood loss than for procedures such as coronary artery bypass graft surgery.
Low plasma fibrinogen levels in patients undergoing cardiac surgery are associated with increased postoperative blood loss. 7, [12] [13] [14] Consequently, fibrinogen replacement therapy targeting a high-normal level of plasma fibrinogen and fibrin-based clot formation may be an important first step in restoring hemostasis during major bleeding after CPB. Fibrinogen replacement therapy may involve transfusion with fresh-frozen plasma (FFP) or cryoprecipitate. However, FFP has a low and variable concentration of fibrinogen 15 and cannot be used when targeting a highnormal plasma fibrinogen level. 8 Furthermore, the hemostatic efficacy of FFP has been questioned. 16, 17 Cryoprecipitate has been withdrawn from many countries because of safety concerns, 18 and although it remains an option in some countries, it is not appropriate as first-line hemostatic therapy. Fibrinogen concentrate may be used for fibrinogen replacement and, unlike cryoprecipitate, undergoes purification and virus inactivation/removal steps during manufacturing. Fibrinogen concentrate is widely used for congenital fibrinogen deficiencies and reported to be potentially effective in acquired hypofibrinogenemia. 16, 19 Clinical evidence from prospective randomized trials is needed to demonstrate the efficacy of fibrinogen concentrate in controlling perioperative bleeding.
Our group performed a double-blind, randomized, placebo-controlled trial to investigate the efficacy of goal-directed, FIBTEM-guided fibrinogen concentrate as first-line hemostatic therapy during aortic replacement surgery. To be included in the study, patients had to exhibit clinically relevant bleeding before administration of fibrinogen concentrate or placebo, determined by measurement of the rate of coagulopathic bleeding after CPB discontinuation and reversal of heparin anticoagulation. Further measurements of the rate of bleeding were recorded after fibrinogen concentrate or placebo administration and again after cycles of additional hemostatic therapy (transfusion with FFP/platelets) for patients in the placebo group. The main aim of this investigation was to examine changes in the rate of bleeding recorded before and after administration of fibrinogen concentrate or placebo to determine whether fibrinogen concentrate is more effective than placebo in controlling coagulopathic bleeding (ie, achieves a greater reduction in the rate of bleeding). Additional analyses are presented that compare the reduction in the rate of bleeding after fibrinogen concentrate infusion with that achieved by transfusion of FFP or platelets in patients in the placebo group. Treatment with fibrinogen concentrate reduced average transfusion requirements for FFP, platelets, and red blood cells, and increased the number of patients avoiding transfusion altogether. 20 
MATERIALS AND METHODS Study Design, Patient Population, and Procedures
This study was conducted at Hannover Medical School, Germany, and was approved by the local Ethics Committee and the German Regulatory Authorities; it was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. The study was assigned Local Ethics Committee reference code 4891M-mono, EudraCT trial number 2007-004612-31, and Clinicaltrials.gov identifier number NCT00701142. Patients aged 18 years or more and scheduled to undergo elective aortic replacement surgery with CPB were screened for eligibility between June 2008 and April 2010. We planned for 60 patients on the basis of a statistical power calculation for analysis of patients' transfusion requirements. 20 Eighty patients were enrolled and randomized to fibrinogen concentrate (FC) or placebo groups by an unblinded pharmacist bound by a confidentiality agreement. Randomization numbers were assigned sequentially, in a 1:1 ratio, with a block size of 4, stratified by surgery type. Sixty-one patients were then included in a prospective, randomized, placebo-controlled study after signed consent had been obtained ( Figure 1 ). Exclusion criteria included patients with congenital or acquired coagulation disorders, previous surgery at the same site, stroke or myocardial infarction within 2 months before surgery, and use of aspirin, clopidogrel, or vitamin K antagonists within 2 to 5 days before surgery. Patients underwent 1 of 3 procedures: aortic valve with root/ascending aorta replacement (n ¼ 21), aortic valve with root/ascending aorta and aortic arch replacement (n ¼ 22), or thoracoabdominal aortic replacement (n ¼ 18).
Intraoperative Measurement of the Rate of Bleeding
After CPB discontinuation, neutralization of heparin using protamine, and surgical control of focal bleeding, the rate of coagulopathic bleeding was measured to assess eligibility for fibrinogen concentrate placebo administration. Patients had received no prior procoagulant therapy. The rate of bleeding was quantified by measuring 5-minute bleeding mass. Dry surgical cloths and compresses were weighed, applied to the surgical area for precisely 5 minutes, and then weighed again. Because the density of blood is approximately 1060 g/L, 21 1 g of recorded mass represents approximately 1 mL of lost blood. We have previously used this approach to assess intraoperative bleeding during aortic surgery. 8, 10 On the basis of experiences at Hannover Medical School, bleeding in the range of 60 to 250 g/5 min ($680-2800 mL/h), where macrovascular bleeding is not evident, indicates coagulopathic bleeding of the microvasculature that cannot be surgically controlled. Patients with a rate of bleeding in this range were included in the study ( Figure 1 ).
Administration of Hemostatic Therapies and Further Assessment of Bleeding
Measurement of bleeding and administration of hemostatic intervention were continuously alternating processes ( Figure 2 ). In the 5 minutes after the first measurement, patients with clinically relevant bleeding were infused with fibrinogen concentrate (FC group, n = 29) or an equivalent volume of 0.9% saline (placebo group, n ¼ 32). Fibrinogen concentrate dosing was guided by FIBTEM maximum clot firmness results, as described previously. [8] [9] [10] Medication was prepared by the unblinded pharmacist, and opaque perfusion syringes were delivered to the operating room labeled with subject and study identification numbers. The content of each syringe (either 50 mL of 0.9% saline as placebo or 1 g fibrinogen concentrate dissolved in 50 mL water for injection) was administered in less than 20 seconds. The median total dose was 8 g (minimum 3 g, maximum 14 g). Anesthesiologists and surgical staff were blinded to therapy. In the 5 minutes after infusion, the second measurement of bleeding was recorded; if less than 60 g/5 min, hemostasis was considered achieved, and surgery proceeded to Abbreviations and Acronyms CPB ¼ cardiopulmonary bypass FC ¼ fibrinogen concentrate group FFP ¼ fresh-frozen plasma Drate ¼ change in the rate of bleeding completion. When the rate of bleeding remained 60 g or more/5 min, patients were treated using a predefined transfusion algorithm: If platelet count at removal of the aortic clamp was less than 100,000/mL, 2 units of apheresis platelet concentrate were administered; for a platelet count of 100,000/mL or more, 4 units of FFP were administered. During the 5 minutes after transfusion, the rate of bleeding was measured for a third time and a second transfusion cycle was then administered to patients still bleeding 60 g or more/5 min. Two units of platelets were given to patients who received 4 units FFP in the first transfusion cycle, and vice versa. The fourth measurement was recorded in the 5 minutes immediately after this second transfusion cycle, and patients with coagulopathic bleeding continued to receive further cycles of concurrent transfusion with FFP and platelets. Because of the decreasing number of patients requiring extended therapy, meaningful statistical analysis of later interventions and their subsequent effects on bleeding could not be performed. Several patients in the FC group went on to receive FFP or platelets after the second bleeding rate measurement. However, only the first and second measurements of the rate of bleeding (ie, at baseline and post-fibrinogen concentrate) are analyzed for patients in the FC group in this report, because meaningful assessment of changes in the rate of bleeding after FFP/platelet transfusions would be confounded by the initial fibrinogen concentrate administration.
Statistical Analysis
To determine the hemostatic effects of fibrinogen concentrate and placebo, the change in the rate of bleeding (Drate) from the first measurement (pre-infusion) to the second measurement (post-infusion) was calculated ( Figure 2 ) for all patients in both groups. All data were normally distributed so the Drate for each group is presented as mean (standard deviation). Individual Drate values were compared between groups using an unpaired t test. Randomized (n=80) FIGURE 1. CONSORT flow diagram of patient progression through this parallel, randomized trial. *Patients did not receive the allocated intervention because the rate of bleeding was less than 60 g/5 min or more than 250 g/5 min, FIBTEM maximum clot firmness was greater than the 22-mm target level, or because there was a late decision not to proceed with aortic replacement surgery. was higher for the FC group than for the placebo group; to allow for this, a Welch correction was used. This analysis was a prespecified efficacy end point.
To determine the hemostatic effect of 1 cycle of transfusion (4 units FFP or 2 units platelets), the Drate from the second measurement (pre-transfusion cycle 1) to the third measurement (post-transfusion cycle 1) of the rate of bleeding was calculated. This calculation was performed using only the placebo group. By using the individual Drate values calculated for 1 transfusion cycle, the hemostatic effects of fibrinogen concentrate versus 1 transfusion cycle were compared as described for fibrinogen concentrate versus placebo. The hemostatic effects of 1 transfusion cycle versus placebo (a within-group comparison) were compared using a paired t test.
To determine the hemostatic effect of 2 cycles of transfusion (total of 4 units FFP and 2 units platelets), the Drate from the second measurement (pre-transfusion cycle 1) to the fourth measurement (post-transfusion cycle 2) of the rate of bleeding was calculated. This was performed for the 30 of 32 patients in the placebo group who received 2 cycles of transfusion; no patients in the FC group were included. By using the individual Drate values calculated for 2 transfusion cycles, the hemostatic effects of fibrinogen concentrate versus 2 transfusion cycles were compared as described for fibrinogen concentrate versus placebo. The hemostatic effects of 2 transfusion cycles versus placebo were compared using a paired t test. Trend lines on graphs represent linear regressions performed using Microsoft Excel (Microsoft Corp, Redmond, Wash).
RESULTS

Patient Demographics
Most patients were male (FC group, 66%; placebo group, 78%), and there were no major differences in 
Comparing the Hemostatic Effects of Fibrinogen Concentrate Versus Placebo
Before treatment, each group had similar mean (standard deviation) baseline rates of coagulopathic bleeding: placebo group, 121 (50) g/5 min; FC group, 116 (46) g/ 5 min. This is visible in Figure 3 , A, where the values for the placebo and FC groups are comparably distributed along the x-axis. Thus, there were no obvious differences in bleeding between the 2 groups before infusion of placebo or fibrinogen concentrate, which would be expected to cause different hemostatic responses.
Mean Drate was assessed post-infusion. A negative Drate value indicates a reduction in the rate of bleeding, whereas a positive value indicates an increase ( Figure 3) . Placebo treatment displayed a negligible effect on coagulopathic bleeding, with the rate of bleeding increasing by 0.4 g/5 min ($5 mL/h) ( Table 1) . After infusion with fibrinogen concentrate, the mean Drate indicated a reduction in the rate of bleeding of 48 g/5 min (Table 1) , approximately equivalent to 550 mL/h. More pronounced reduction in the rate of bleeding was typically observed for patients exhibiting a higher rate of bleeding before fibrinogen concentrate infusion. Statistical comparison confirmed that fibrinogen concentrate was more effective than placebo for controlling intraoperative bleeding (P <.001, Table 1 ).
Comparing the Hemostatic Effects of 1 Cycle of Transfusion (Fresh-Frozen Plasma or Platelets) Versus Placebo
All patients in the placebo group (32/32) received at least 1 cycle of transfusion with 4 units FFP or 2 units platelet concentrate. Because placebo infusion had little effect on the rate of bleeding, the hemostatic effect of FFP/platelet transfusion could be assessed by monitoring subsequent changes in the rate of bleeding. As a baseline for determining Drate after 1 cycle of transfusion, the second measurement of the rate of bleeding was used (Figure 2 ). This value was recorded immediately before FFP/platelet transfusion, and the mean (standard deviation) rate of bleeding for the placebo group at this time was 122 (55) g/5 min, which was comparable with the rate of bleeding observed before placebo infusion. After FFP/platelets transfusion, there was an overall decrease in the rate of bleeding (Figure 3, B) . The mean Drate (Table 1) indicated that 1 transfusion cycle reduced the rate of coagulopathic bleeding by 16 g/5 min, equivalent to approximately 180 mL/h. This reduction was significant compared with placebo (P ¼ .004, Table 1 ).
Comparing the Hemostatic Effects of 2 Cycles of Transfusion (Fresh-Frozen Plasma and Platelets) Versus Placebo
In the placebo group, 30 of 32 patients received a second cycle of transfusion, in which patients were given whichever therapy was not received in the first cycle. Consequently, all 30 patients undergoing 2 cycles of transfusion received a total of 4 units FFP and 2 units platelets. The hemostatic effect of this combination was assessed by calculating the Drate between the measurements made before any transfusion (second measurement) and after 2 cycles of transfusion (fourth measurement). Transfusion with 4 units FFP plus 2 units platelets led to an overall reduction in the rate of bleeding of 28 g/5 min (Figure 3, B) , equivalent to approximately 320 mL/h. This reduction was also significant compared with placebo (P ¼ .002, Table 1 ).
Comparing the Hemostatic Effects of Fibrinogen
Although the first cycle of transfusion had a positive hemostatic effect, statistical comparison revealed that the reduction in the rate of bleeding observed after transfusion with FFP or platelets was significantly less than the reduction in the rate of bleeding observed after fibrinogen concentrate infusion (P ¼ .003, Table 1 ).
Comparing the Hemostatic Effects of Fibrinogen Concentrate Versus 2 Cycles of Transfusion (FreshFrozen Plasma and Platelets)
The decrease in the rate of bleeding after 2 cycles of transfusion (28 g/5 min, $320 mL/h) was also not as great as that seen after treatment with fibrinogen concentrate (48 g/5 min, $550 mL/h); however, this difference did not reach statistical significance (P ¼ .11, Table 1 ).
DISCUSSION
In this single-center, prospective, randomized, doubleblind, placebo-controlled study, we used 5-minute bleeding mass to accurately quantify the rate of coagulopathic bleeding in patients undergoing major aortic replacement surgery. This unique tool has never before been used in a prospective, randomized study. We successfully used 5-minute bleeding mass as a marker of the beginning (!60 g/5 min) and end (<60 g/5 min) of clinically relevant coagulopathic bleeding and of the patient's response to hemostatic therapy, avoiding the need to rely on subjective measures. Our results show that FIBTEM-guided intraoperative hemostatic monotherapy with fibrinogen concentrate is more effective than placebo, 4 units FFP, or 2 units platelets, and is at least as effective as 4 units FFP plus 2 units platelets in reducing the rate of coagulopathic bleeding during major aortic replacement surgery.
That FIBTEM-guided fibrinogen concentrate as first-line hemostatic therapy led to a significant reduction in the rate of bleeding explains why patients who received fibrinogen concentrate required fewer transfusions with allogeneic blood products than patients who received placebo. 20 The difference in mean values suggests that fibrinogen concentrate may be more effective than even 2 transfusion cycles of FFP/platelets. It will be interesting to see whether this is confirmed in the Phase III REPLACE study (NCT01475669). Of note is that 4 units FFP plus 2 units platelets takes substantially longer to administer than 1 infusion with fibrinogen concentrate, and this is an important consideration when control of acute bleeding is urgently required. Whereas allogeneic blood products must be crossmatched and thawed, and large volumes given, fibrinogen concentrate can be stored at room temperature, rapidly reconstituted, and infused as a smaller volume. In addition, fibrinogen concentrate avoids many of the safety issues associated with allogeneic blood products, such as transfusion-related acute lung injury, transfusionassociated circulatory overload, acute respiratory distress syndrome, and transfusion-related immunomodulation. [22] [23] [24] The benefits of targeted, individualized dosing of fibrinogen concentrate are evident in that changes in the rate of bleeding were more pronounced for patients with a high initial rate. This was evident to a lesser degree after transfusion with FFP/platelets, where dosing was fixed and not tailored to the individual patient. Consistent with previous studies in cardiac surgery 8, 10, 25 and trauma, 26 our findings demonstrate the benefit of using a target FIBTEM maximum clot firmness value to guide appropriate dosing of fibrinogen concentrate. This ''theragnostic'' approach integrates rapid diagnostic testing with drug therapy, ensuring that fibrinogen concentrate is administered and dosed in line with patients' actual needs. Two systematic reviews, which included several prospective studies in cardiovascular surgery, concluded that fibrinogen concentrate therapy could increase clot firmness and decrease transfusion requirements, blood loss, and postoperative drainage volumes.
16,19
Study Limitations
A limitation of the present analyses is that different timepoints were used as the baseline from which to measure the hemostatic effect of treatment with FFP/platelets than were used when measuring the effects of fibrinogen concentrate and placebo; however, we did ensure before performing the comparisons that the baseline values were comparable for both groups and at both time-points. We cannot rule out the possibility of selection bias in using ''nonresponders'' from the placebo group for the assessment of 2 transfusion cycles (FFP and platelets). However, this is expected to have had little impact, because the majority (30/ 32, 94%) of patients in the placebo group were ''nonresponders'' (ie, went on to receive a second cycle of transfusion). In addition, only comparisons of Drate after administration of fibrinogen concentrate or placebo represent comparisons between prespecified efficacy end points. Comparisons of placebo or fibrinogen concentrate versus 1 or 2 cycles of transfusion are exploratory analyses that warrant further prospective investigation. Although 5-minute bleeding mass as a tool to quantify the rate of intraoperative coagulopathic bleeding has not been used in a prospective, randomized trial, our group has successfully used it in small prospective aortic surgery studies. 8, 10 The present study provides further evidence that this method yields accurate and reproducible measurements.
CONCLUSIONS
A single, targeted dose of fibrinogen concentrate after discontinuation of CPB controls coagulopathic bleeding during aortic surgery more effectively than placebo or a standardized treatment algorithm of 4 units FFP or 2 units apheresis platelets. Fibrinogen concentrate also enables more rapid and at least as effective control of intraoperative bleeding when compared with transfusion of 4 units FFP and 2 units platelets. These findings support the use of goal-directed, FIBTEMguided fibrinogen concentrate as a rapid and efficacious first-line hemostatic therapy in patients with coagulopathic bleeding undergoing major aortic replacement surgery.
